Factory 99% Finerenone Powder CAS 1050477-31-0 Chemical Intermediate Finerenone

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A994
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Finerenone
• CAS: 1050477-31-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Finerenone
Appearance	White Powder
CAS NO.	1050477-31-0
Storage	Keep in a cool, dry, dark location

 

Finerenone (BAY 94-8862) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) designed to block excessive mineralocorticoid receptor (MR) activation. This overactivation drives inflammation and fibrosis in tissues such as the kidneys, heart, and blood vessels, exacerbating conditions like chronic kidney disease (CKD) and heart failure (HF). By inhibiting MR-mediated sodium retention and pathological pathways, finerenone mitigates organ damage without the high potassium risk (hyperkalemia) associated with older MRA therapies.

 

1. Diabetic Kidney Disease (DKD): Approved in the US (2021) and EU (2022) to reduce the risk of kidney failure, eGFR decline, and cardiovascular events in adults with T2D and CKD (eGFR 25-75 mL/min/1.73 m² with albuminuria).
2. Heart Failure (HF): Under priority review by the FDA for treating adults with HF and left ventricular ejection fraction (LVEF) ≥40% (HFmrEF/HFpEF), based on Phase III FINEARTS-HF trial data showing reduced cardiovascular mortality and hospitalization.
3. Chronic Kidney Disease (CKD): Investigated in non-diabetic populations (FIND-CKD trial) to assess efficacy in broader CKD cohorts beyond T2D.

1. Anti-fibrotic and Anti-inflammatory: Blocks MR-induced profibrotic gene transcription and inflammatory cytokine release in renal and cardiac tissues, slowing disease progression.
2. Cardiorenal Protection: Lowers urinary albumin-to-creatinine ratio (UACR) and stabilizes eGFR in DKD, while reducing cardiovascular events (e.g., heart failure hospitalization, myocardial infarction) in HFmrEF/HFpEF.
3. Improved Safety Profile: Selective MR antagonism and non-steroidal structure reduce hyperkalemia risk, enabling safer long-term use compared to steroid-based MRAs (e.g., spironolactone).